These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21730163)

  • 1. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.
    Huang L; Yan Z; Liao X; Li Y; Yang J; Wang ZG; Zuo Y; Kawai H; Shadfan M; Ganapathy S; Yuan ZM
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12001-6. PubMed ID: 21730163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
    Tian H; Tackmann NR; Jin A; Zheng J; Zhang Y
    J Biol Chem; 2017 Dec; 292(52):21614-21622. PubMed ID: 29123033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDMX is essential for the regulation of p53 protein levels in the absence of a functional MDM2 C-terminal tail.
    Sanford JD; Yang J; Han J; Tollini LA; Jin A; Zhang Y
    BMC Mol Cell Biol; 2021 Sep; 22(1):46. PubMed ID: 34551723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.
    Zhang Y; Zeng SX; Hao Q; Lu H
    Dev Biol; 2017 Mar; 423(1):34-45. PubMed ID: 28118981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.
    Gu J; Kawai H; Nie L; Kitao H; Wiederschain D; Jochemsen AG; Parant J; Lozano G; Yuan ZM
    J Biol Chem; 2002 May; 277(22):19251-4. PubMed ID: 11953423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.
    Itahana K; Mao H; Jin A; Itahana Y; Clegg HV; Lindström MS; Bhat KP; Godfrey VL; Evan GI; Zhang Y
    Cancer Cell; 2007 Oct; 12(4):355-66. PubMed ID: 17936560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
    FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.
    Zhang Y; Zhang X; Lu H
    Dev Biol; 2014 Dec; 396(1):19-30. PubMed ID: 25263199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.
    Ohtsubo C; Shiokawa D; Kodama M; Gaiddon C; Nakagama H; Jochemsen AG; Taya Y; Okamoto K
    Cancer Sci; 2009 Jul; 100(7):1291-9. PubMed ID: 19432880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of the first small molecule inhibitor of MDMX.
    Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
    J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
    Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
    Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse modelling of the MDM2/MDMX-p53 signalling axis.
    Tackmann NR; Zhang Y
    J Mol Cell Biol; 2017 Feb; 9(1):34-44. PubMed ID: 28096294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
    Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
    Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.